A
Annexon Biosciences
Biotech & Life Sciences · San Francisco, United States · Founded 2011 · IPO 2020
Biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders MoreLess
Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and neurodegenerative diseases, including eye-related conditions. The company operates in the biopharmaceutical market, targeting diseases such as Alzheimer's, Huntington's, and glaucoma.
Annexon's unique approach centers on the classical complement pathway, a part of the immune system that, when improperly activated, can lead to tissue damage. Their primary focus is on inhibiting C1q, the molecule that initiates this pathway. By blocking C1q, Annexon aims to prevent the cascade of events that cause disease progression, effectively "stopping the start" of these conditions.
The company's business model involves extensive research and development (R&D) to create these novel therapies. They conduct clinical trials to test the safety and effectiveness of their treatments. Once a therapy proves successful, Annexon can either bring it to market themselves or partner with larger pharmaceutical companies to distribute it. This model allows them to generate revenue through product sales, licensing agreements, and milestone payments from partners.
Annexon's clients primarily include patients suffering from autoimmune and neurodegenerative diseases, healthcare providers, and larger pharmaceutical companies looking for innovative treatments to add to their portfolios. The company recently secured $100 million in financing to advance its pipeline of therapies, highlighting strong investor confidence in their approach and potential.
In summary, Annexon Biosciences is at the forefront of developing first-in-class therapies targeting the classical complement pathway to treat a range of serious diseases. Their innovative approach and strong financial backing position them well in the competitive biopharmaceutical market.
Keywords: biopharmaceutical, autoimmune, neurodegenerative, therapies, C1q inhibitor, classical complement pathway, Alzheimer's, Huntington's, glaucoma, clinical trials.
Company overview
Annexon Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2011
- Headquarters
- San Francisco, United States
- Employees
- 116
- Open positions
- 4
- Dealroom signal
- 34.4
Valuation & funding
Annexon Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Nov 2025 | $75M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jun 2024 | $125M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Dec 2023 | $125M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | Jul 2022 | $130M | — | Undisclosed | ↗ |
| IPOOther financing | Jul 2020 | $0 | — | Undisclosed | — |
| SERIES COther financing | Jul 2020 | Bain Capital · Farallon Capital Management · NEA · Adage Capital | — | ||
| SERIES COther financing | Dec 2018 | Blackstone · NEA · Citadel · Satter Investment Management | ↗ | ||
| SERIES BOther financing | Jun 2016 | NEA · Correlation Ventures · Clarus Ventures · Novartis Venture Fund | — | ||
| SERIES AOther financing | Dec 2014 | Clarus Ventures · Novartis Venture Fund | — | ||
| SEEDOther financing | Aug 2011 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$214M | — |
| 2025 | $0 | — | −$214M | — |
| 2024 | $0 | — | −$151M | — |
| 2023 | $0 | — | −$142M | — |
| 2022 | $0 | — | −$146M | — |
| 2021 | $0 | — | −$131M | — |
| 2020 | $0 | — | −$63M | — |
Growth signals
Annexon Biosciences website traffic
Latest recorded traffic for Annexon Biosciences is 4.9K monthly website visits, down 41.7% over the last three months. Annexon Biosciences's team declined 2.5% over the past year.
Hiring
Open positions at Annexon Biosciences
Current openings linked to this company in Dealroom.
Comparisons
Annexon Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Annexon Biosciences's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Annexon Biosciences has talent and traffic
team presence
In the news
Latest news about Annexon Biosciences
Recent press, funding announcements, and product moves mentioning Annexon Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about Annexon Biosciences
An AI-synthesized read of the highest-engagement posts about Annexon Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Annexon Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.